Up to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported a way to track changes with whole-tissue biospy phenotyping.
The European Biotech market is extremely dynamic, acknowledged as being number two in the world of market rankings. This is a cause for celebration!
Belgian nanobody developer Ablynx NVs nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP), paving the way to market authorisation in Europe and the US.
Active sampling of airborne viruses, bacteria, yeasts and fungi.